Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow Conversion Efficiency
Drugs Made In America Acquisition II Corp. Ordinary Shares cash flow conversion efficiency. Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has a cash flow conversion efficiency ratio of 0.000x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-172.75K) by net assets ($495.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
Cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Drugs Made In America Acquisition II Cor share price for real-time trading data and today's change.
Drugs Made In America Acquisition II Corp. Ordinary Shares Cash Flow Conversion Ratio Explained
Drugs Made In America Acquisition II Corp. Ordinary Shares cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their cash flow conversion efficiency. Also see Drugs Made In America Acquisition II Cor market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Huarui Electrical Appliance Co Ltd
SHE:300626
|
-0.015x |
|
Jiangyin Haida Rubber and Plastic Co Ltd Class A
SHE:300320
|
0.016x |
|
ChemPartner PharmaTech Co Ltd
SHE:300149
|
0.022x |
|
Zero One Technology Co Ltd
TW:3029
|
-0.020x |
|
Pet Acquisition LLC
NASDAQ:WOOF
|
-0.051x |
|
ChongQing Zhengchuan Pharmaceutical Packaging Co Ltd
SHG:603976
|
0.038x |
|
Thermador Groupe SA
PA:THEP
|
0.062x |
|
Birla Corporation Limited
NSE:BIRLACORPN
|
0.030x |
Annual Cash Flow Conversion Efficiency for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2025)
The table below shows the annual cash flow conversion efficiency of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2025. Review financial agility of Drugs Made In America Acquisition II Cor to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $487.16 Million | $-1.02 Million | -0.002x | -100.13% |
| 2024-12-31 | $-116.72K | $-194.30K | 1.665x | -- |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp… Read more